Similar articles

• Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.

  Roviello G, Generali D. Roviello G, et al. Eur Urol. 2017 Dec;72(6):1027-1028. doi: 10.1016/j.eururo.2017.07.019. Epub 2017 Jul 29. Eur Urol. 2017. PMID: 28760645 No abstract available.
• NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma.

  Elsada A, Adler AI. Elsada A, et al. Lancet Oncol. 2017 Sep;18(9):1153-1154. doi: 10.1016/S1470-2045(17)30590-9. Epub 2017 Aug 8. Lancet Oncol. 2017. PMID: 28800862 No abstract available.
• Cabozantinib improves clinical outcomes in renal cancer.

  Das M. Das M. Lancet Oncol. 2017 Jan;18(1):e2. doi: 10.1016/S1470-2045(16)30620-9. Epub 2016 Nov 25. Lancet Oncol. 2017. PMID: 27890466 No abstract available.
• Cabozantinib use in renal cell carcinoma.

  Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW. Neuwelt AJ, et al. Drugs Today (Barc). 2017 May;53(5):299-307. doi: 10.1358/dot.2017.53.5.2623107. Drugs Today (Barc). 2017. PMID: 28650002 Review.
• Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

  Schmidinger M, Danesi R. Schmidinger M, et al. Oncologist. 2018 Mar;23(3):306-315. doi: 10.1634/theoncologist.2017-0335. Epub 2017 Nov 16. Oncologist. 2018. PMID: 29146618 Free PMC article. Review.